Next Article in Journal
SMA-Assisted Exfoliation of Graphite by Microfluidization for Efficient and Large-Scale Production of High-Quality Graphene
Previous Article in Journal
Surface Morphology-Dependent Functionality of Titanium Dioxide–Nickel Oxide Nanocomposite Semiconductors
Previous Article in Special Issue
Ion Release and Surface Characterization of Nanostructured Nitinol during Long-Term Testing
Open AccessArticle

Doxorubicin·Hydrochloride/Cisplatin-Loaded Hydrogel/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo

1
Department of Orthopedic Surgery, Chonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju 54907, Korea
2
Department of Biochemistry and Molecular Biology, Chonbuk National University Medical School, Jeonju 54896, Korea
3
Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
4
Institute of Cell and Tissue Engineering, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea
*
Author to whom correspondence should be addressed.
Nanomaterials 2019, 9(12), 1652; https://doi.org/10.3390/nano9121652
Received: 27 September 2019 / Revised: 18 November 2019 / Accepted: 20 November 2019 / Published: 21 November 2019
(This article belongs to the Special Issue Biomedical Applications of Nanotechnology)
Osteosarcoma (OSA) is a difficult cancer to treat due to its tendency for relapse and metastasis; advanced methods are therefore required for OSA treatment. In this study, we prepared a local drug-delivery system for OSA treatment based on doxorubicin·hydrochloride (DOX·HCl)/cisplatin (CP)-loaded visible light-cured glycol chitosan (GC) hydrogel/(2-hydroxypropyl)-beta-cyclodextrin (GDHCP), and compared its therapeutic efficiency with that of DOX·HCl- and CP-loaded GC hydrogels (GD and GHCP). Because of diffusion driven by concentration gradients in the swollen matrix, the three hydrogels showed sustained releases of DOX·HCl and CP over 7 days, along with initial 3-h bursts. Results of in vitro cell viability and in vivo animal testing revealed that GDHCP had a stronger anticancer effect than GD and GHCP even though there were no significant differences. Body weight measurement and histological evaluations demonstrated that the drug-loaded GC hydrogels had biocompatibility without cardiotoxicity or nephrotoxicity. These results suggested that GDHCP could be a good platform as a local drug-delivery system for clinical use in OSA treatment.
Keywords: osteosarcoma; visible light-cured glycol chitosan hydrogel; (2-hydroxypropyl)-beta-cyclodextrin; doxorubicin·hydrochloride; cisplatin; local drug delivery system; cardiotoxicity; nephrotoxicity osteosarcoma; visible light-cured glycol chitosan hydrogel; (2-hydroxypropyl)-beta-cyclodextrin; doxorubicin·hydrochloride; cisplatin; local drug delivery system; cardiotoxicity; nephrotoxicity
MDPI and ACS Style

Yoon, S.J.; Moon, Y.J.; Chun, H.J.; Yang, D.H. Doxorubicin·Hydrochloride/Cisplatin-Loaded Hydrogel/Nanosized (2-Hydroxypropyl)-Beta-Cyclodextrin Local Drug-Delivery System for Osteosarcoma Treatment In Vivo . Nanomaterials 2019, 9, 1652.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop